Your browser doesn't support javascript.
loading
Effect of Vitamin C, Thiamine, and Hydrocortisone on Ventilator- and Vasopressor-Free Days in Patients With Sepsis: The VICTAS Randomized Clinical Trial.
Sevransky, Jonathan E; Rothman, Richard E; Hager, David N; Bernard, Gordon R; Brown, Samuel M; Buchman, Timothy G; Busse, Laurence W; Coopersmith, Craig M; DeWilde, Christine; Ely, E Wesley; Eyzaguirre, Lindsay M; Fowler, Alpha A; Gaieski, David F; Gong, Michelle N; Hall, Alex; Hinson, Jeremiah S; Hooper, Michael H; Kelen, Gabor D; Khan, Akram; Levine, Mark A; Lewis, Roger J; Lindsell, Chris J; Marlin, Jessica S; McGlothlin, Anna; Moore, Brooks L; Nugent, Katherine L; Nwosu, Samuel; Polito, Carmen C; Rice, Todd W; Ricketts, Erin P; Rudolph, Caroline C; Sanfilippo, Fred; Viele, Kert; Martin, Greg S; Wright, David W.
Afiliação
  • Sevransky JE; Division of Pulmonary, Allergy, Critical Care, and Sleep, Emory University School of Medicine, Atlanta, Georgia.
  • Rothman RE; Emory Critical Care Center, Emory Healthcare, Atlanta, Georgia.
  • Hager DN; Department of Emergency Medicine, Johns Hopkins University, Baltimore, Maryland.
  • Bernard GR; Division of Pulmonary Critical Care, Johns Hopkins University, Baltimore, Maryland.
  • Brown SM; Division of Pulmonary Critical Care, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Buchman TG; Division of Pulmonary Critical Care, Intermountain Medical Center and University of Utah, Salt Lake City.
  • Busse LW; Emory Critical Care Center, Emory Healthcare, Atlanta, Georgia.
  • Coopersmith CM; Department of Surgery, Emory University School of Medicine, Atlanta, Georgia.
  • DeWilde C; Division of Pulmonary, Allergy, Critical Care, and Sleep, Emory University School of Medicine, Atlanta, Georgia.
  • Ely EW; Emory Critical Care Center, Emory Healthcare, Atlanta, Georgia.
  • Eyzaguirre LM; Emory Critical Care Center, Emory Healthcare, Atlanta, Georgia.
  • Fowler AA; Department of Surgery, Emory University School of Medicine, Atlanta, Georgia.
  • Gaieski DF; Division of Pulmonary Critical Care, Virginia Commonwealth University, Richmond.
  • Gong MN; Division of Pulmonary Critical Care, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Hall A; Johns Hopkins Critical Illness, Brain Dysfunction, and Survivorship (CIBS) Center, Baltimore, Maryland.
  • Hinson JS; Veteran's Affairs Tennessee Valley Geriatric Research Education Clinical Center (GRECC), Nashville.
  • Hooper MH; Division of Brain Injury Outcomes, Johns Hopkins University, Baltimore, Maryland.
  • Kelen GD; Division of Pulmonary Critical Care, Virginia Commonwealth University, Richmond.
  • Khan A; Department of Emergency Medicine, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.
  • Levine MA; Department of Critical Care, Montefiore Medical Center, Bronx, New York.
  • Lewis RJ; Department of Emergency Medicine, Emory University, Atlanta, Georgia.
  • Lindsell CJ; Department of Emergency Medicine, Johns Hopkins University, Baltimore, Maryland.
  • Marlin JS; Division of Pulmonary Critical Care, Sentara Healthcare, Norfolk, Virginia.
  • McGlothlin A; Department of Emergency Medicine, Johns Hopkins University, Baltimore, Maryland.
  • Moore BL; Division of Pulmonary Critical Care, Oregon Health & Science University, Portland.
  • Nugent KL; Molecular and Clinical Nutrition Section, National Institutes of Health, Bethesda, Maryland.
  • Nwosu S; Department of Emergency Medicine, Harbor-UCLA Medical Center, Torrance, California.
  • Polito CC; Berry Consultants LLC, Austin, Texas.
  • Rice TW; Department of Emergency Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.
  • Ricketts EP; Lundquist Institute for Biomedical Innovation, Torrance, California.
  • Rudolph CC; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Sanfilippo F; Vanderbilt Coordinating Center, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Viele K; Berry Consultants LLC, Austin, Texas.
  • Martin GS; Department of Emergency Medicine, Emory University, Atlanta, Georgia.
  • Wright DW; Department of Emergency Medicine, Emory University, Atlanta, Georgia.
JAMA ; 325(8): 742-750, 2021 02 23.
Article em En | MEDLINE | ID: mdl-33620405
ABSTRACT
Importance Sepsis is a common syndrome with substantial morbidity and mortality. A combination of vitamin C, thiamine, and corticosteroids has been proposed as a potential treatment for patients with sepsis.

Objective:

To determine whether a combination of vitamin C, thiamine, and hydrocortisone every 6 hours increases ventilator- and vasopressor-free days compared with placebo in patients with sepsis. Design, Setting, and

Participants:

Multicenter, randomized, double-blind, adaptive-sample-size, placebo-controlled trial conducted in adult patients with sepsis-induced respiratory and/or cardiovascular dysfunction. Participants were enrolled in the emergency departments or intensive care units at 43 hospitals in the United States between August 2018 and July 2019. After enrollment of 501 participants, funding was withheld, leading to an administrative termination of the trial. All study-related follow-up was completed by January 2020.

Interventions:

Participants were randomized to receive intravenous vitamin C (1.5 g), thiamine (100 mg), and hydrocortisone (50 mg) every 6 hours (n = 252) or matching placebo (n = 249) for 96 hours or until discharge from the intensive care unit or death. Participants could be treated with open-label corticosteroids by the clinical team, with study hydrocortisone or matching placebo withheld if the total daily dose was greater or equal to the equivalent of 200 mg of hydrocortisone. Main Outcomes and

Measures:

The primary outcome was the number of consecutive ventilator- and vasopressor-free days in the first 30 days following the day of randomization. The key secondary outcome was 30-day mortality.

Results:

Among 501 participants randomized (median age, 62 [interquartile range {IQR}, 50-70] years; 46% female; 30% Black; median Acute Physiology and Chronic Health Evaluation II score, 27 [IQR, 20.8-33.0]; median Sequential Organ Failure Assessment score, 9 [IQR, 7-12]), all completed the trial. Open-label corticosteroids were prescribed to 33% and 32% of the intervention and control groups, respectively. Ventilator- and vasopressor-free days were a median of 25 days (IQR, 0-29 days) in the intervention group and 26 days (IQR, 0-28 days) in the placebo group, with a median difference of -1 day (95% CI, -4 to 2 days; P = .85). Thirty-day mortality was 22% in the intervention group and 24% in the placebo group. Conclusions and Relevance Among critically ill patients with sepsis, treatment with vitamin C, thiamine, and hydrocortisone, compared with placebo, did not significantly increase ventilator- and vasopressor-free days within 30 days. However, the trial was terminated early for administrative reasons and may have been underpowered to detect a clinically important difference. Trial Registration ClinicalTrials.gov Identifier NCT03509350.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ácido Ascórbico / Respiração Artificial / Tiamina / Vitaminas / Hidrocortisona / Sepse / Anti-Inflamatórios Tipo de estudo: Clinical_trials / Etiology_studies / Prognostic_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: JAMA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Geórgia

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ácido Ascórbico / Respiração Artificial / Tiamina / Vitaminas / Hidrocortisona / Sepse / Anti-Inflamatórios Tipo de estudo: Clinical_trials / Etiology_studies / Prognostic_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: JAMA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Geórgia
...